肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Drug Safety:钙通道阻滞剂或增加肺癌风险

2018-03-22 徐晓涵 环球医学网

钙通道阻滞剂增加肺癌风险
关注

发表在《Drug Saf》的一项由以色列和加拿大科学家进行的观察性研究的系统评价和Meta分析，考察了钙通道阻滞剂（CCB）与肺癌风险之间的相关性。

发表在《Drug Saf》的一项由以色列和加拿大科学家进行的观察性研究的系统评价和Meta分析，考察了钙通道阻滞剂（CCB）与肺癌风险之间的相关性。

介绍：CCB的使用与肺癌风险之间相关性的结果相互矛盾。考虑肺癌预防的公共卫生的重要性，以及越来越多的证据显示，调节钙离子通道在肺癌进展中的显着生物作用，研究者进行了一项Meta分析，旨在评估CCB使用者vs不使用者的肺癌发病风险。

材料和方法：研究者对主要的医学数据库进行了全面的系统检索，检索内容为发表于2017年12月之前的考察CCB使用和肺癌风险的观察性研究。研究者使用随机效应模型来汇总结果。使用随机效应Meta回归考察CCB使用持续时间对估计效应大小的影响。

结果：分析纳入了10项研究（6项队列，4项病例对照研究），共评估38758例CCB使用者总体癌症风险。CCB使用和肺癌的总体风险比（RR）为1.15（95% 置信区间[CI]，1.01~1.32）。根据CCB使用持续时间进行的亚组分析表明，5项研究结果显示长时间暴露（≥4年）与肺癌风险的增加（RR，1.18；95% CI，1.08~1.30）。

结论：CCBs暴露与肺癌风险的增加相关。考虑到CCB的广泛使用，以及缺乏长期CCB长期暴露的影响数据，因此这些结果需要引起关注并需要进一步调查。
原始出处：
Rotshild V, Azoulay L, Zarifeh M,et al.The Risk for Lung Cancer Incidence with Calcium Channel Blockers: A Systematic Review and Meta-Analysis of Observational Studies.Drug Saf. 2018 Feb 26. doi: 10.1007/s40264-018-0644-4. [Epub ahead of print]

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2061724, encodeId=21192061e2478, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Thu Oct 11 11:20:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793549, encodeId=b70e1e935492d, content=<a href='/topic/show?id=5cc615840e7' target=_blank style='color:#2F92EE;'>#safety#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15840, encryptionId=5cc615840e7, topicName=safety)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Feb 02 06:20:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862305, encodeId=f13b18623052f, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Tue Jul 03 00:20:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085790, encodeId=60912085e9096, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Tue May 08 05:20:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045561, encodeId=3b872045561b8, content=<a href='/topic/show?id=f6cf8225325' target=_blank style='color:#2F92EE;'>#肺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82253, encryptionId=f6cf8225325, topicName=肺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Tue May 01 14:20:00 CST 2018, time=2018-05-01, status=1, ipAttribution=)]
    2018-10-11 sjq027

    #癌风险#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2061724, encodeId=21192061e2478, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Thu Oct 11 11:20:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793549, encodeId=b70e1e935492d, content=<a href='/topic/show?id=5cc615840e7' target=_blank style='color:#2F92EE;'>#safety#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15840, encryptionId=5cc615840e7, topicName=safety)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Feb 02 06:20:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862305, encodeId=f13b18623052f, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Tue Jul 03 00:20:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085790, encodeId=60912085e9096, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Tue May 08 05:20:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045561, encodeId=3b872045561b8, content=<a href='/topic/show?id=f6cf8225325' target=_blank style='color:#2F92EE;'>#肺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82253, encryptionId=f6cf8225325, topicName=肺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Tue May 01 14:20:00 CST 2018, time=2018-05-01, status=1, ipAttribution=)]
    2019-02-02 quxin068

    #safety#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2061724, encodeId=21192061e2478, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Thu Oct 11 11:20:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793549, encodeId=b70e1e935492d, content=<a href='/topic/show?id=5cc615840e7' target=_blank style='color:#2F92EE;'>#safety#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15840, encryptionId=5cc615840e7, topicName=safety)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Feb 02 06:20:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862305, encodeId=f13b18623052f, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Tue Jul 03 00:20:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085790, encodeId=60912085e9096, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Tue May 08 05:20:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045561, encodeId=3b872045561b8, content=<a href='/topic/show?id=f6cf8225325' target=_blank style='color:#2F92EE;'>#肺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82253, encryptionId=f6cf8225325, topicName=肺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Tue May 01 14:20:00 CST 2018, time=2018-05-01, status=1, ipAttribution=)]
    2018-07-03 wangbingxhy

    #Drug#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2061724, encodeId=21192061e2478, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Thu Oct 11 11:20:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793549, encodeId=b70e1e935492d, content=<a href='/topic/show?id=5cc615840e7' target=_blank style='color:#2F92EE;'>#safety#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15840, encryptionId=5cc615840e7, topicName=safety)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Feb 02 06:20:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862305, encodeId=f13b18623052f, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Tue Jul 03 00:20:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085790, encodeId=60912085e9096, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Tue May 08 05:20:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045561, encodeId=3b872045561b8, content=<a href='/topic/show?id=f6cf8225325' target=_blank style='color:#2F92EE;'>#肺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82253, encryptionId=f6cf8225325, topicName=肺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Tue May 01 14:20:00 CST 2018, time=2018-05-01, status=1, ipAttribution=)]
    2018-05-08 zhyy88

    #阻滞剂#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2061724, encodeId=21192061e2478, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Thu Oct 11 11:20:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793549, encodeId=b70e1e935492d, content=<a href='/topic/show?id=5cc615840e7' target=_blank style='color:#2F92EE;'>#safety#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15840, encryptionId=5cc615840e7, topicName=safety)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Feb 02 06:20:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862305, encodeId=f13b18623052f, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Tue Jul 03 00:20:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085790, encodeId=60912085e9096, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Tue May 08 05:20:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045561, encodeId=3b872045561b8, content=<a href='/topic/show?id=f6cf8225325' target=_blank style='color:#2F92EE;'>#肺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82253, encryptionId=f6cf8225325, topicName=肺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Tue May 01 14:20:00 CST 2018, time=2018-05-01, status=1, ipAttribution=)]
    2018-05-01 qidongfanjian

    #肺癌风险#

    0

相关资讯

FDA更新波普瑞韦禁忌症

美国食品药品监督管理局（FDA）于近日更新了波普瑞韦（boceprevir）药物标签，表明波普瑞韦与钙通道阻滞剂、α1-肾上腺素受体拮抗剂相互作用可能有害。 2011年5月，FDA批准蛋白酶抑制剂波普瑞韦用于丙肝的治疗。2012年4月，FDA发出警告，对于HCV和HIV合并感染的患者，波普瑞韦与强效HIV蛋白酶抑制剂Ritonavir（利托那韦）联用可能降低药物对这两种疾病的疗效。 现在，该药

BMJ：ACEI为糖尿病患者**降压药

我国台湾学者简国龙、杜裕康等新近发表的一项荟萃分析显示，血管紧张素转换酶抑制剂（ACEI）在成年糖尿病患者中是首选的抗高血压治疗药物。该研究发表于10月24日的《英国医学杂志》（BMJ）。　　 研究人员通过对PubMed、Medline、Scopus、Cochrane等数据的检索，分析了63项随机试验。这些试验在近37,000位患有糖尿病的成年人中评价了11种不同的降压治疗方案。研究终点

Am J Cardiovasc Drugs：长期抗高血压治疗与卒中预防：荟萃分析

背景：每年卒中引起世界范围内约670万人死亡，是引起死亡的第二大疾病。高血压是卒中独立的危险因素，高血压药物治疗能显著降低卒中的发生率。虽然先前荟萃分析表明：一些抗高血压药物在降低卒中风险方面优于安慰剂，但是具体哪类药物是最有效的尚不清楚。方法：我们在MEDLINE进行系统性搜索1999年到2014年发表的抗高血压药物治疗对卒中一级和或二级预防的随机对照试验（RCT）的文章。五类抗高血压药物为：A

降压类药物临床应用经验汇总 ！

高血压的现代治疗常用药物主要有五大类，即利尿剂、β受体阻滞剂、钙拮抗剂（CCB），血管紧张素转换酶抑制剂（ACEI）、血管紧张素Ⅱ受体拮抗剂（ARB）。另外我国也有一些复方制剂及中药制剂在使用。 1. 利尿药 氢氯噻嗪（噻嗪类利尿药） 12.5毫克/次　　每日1~2次。 氯噻嗪（噻嗪类利尿药） 25~50毫克/次　每日1次。 螺内酯（噻嗪类利尿药）

Chest：治疗脓毒症期间房颤——β受体阻滞剂优于CCBs

脓毒症期间发生房颤（AF）增加发病率和死亡率，但在脓毒症期间有针对性的治疗AF心率和节律的实践模式和结果目前还不清楚。该项回顾性队列研究的数据来自于约20％的美国医院。研究人员确定了脓毒症期间IV级AF治疗的相关因素（β受体阻滞剂[BBs]，钙通道阻滞剂[CCBs]，地高辛，或胺碘酮）。研究人员使用倾向得分匹配和工具变量的方法来比较不同治疗房颤方法之间的死亡率。在39693例脓毒症期间发生房颤的患

Crit Care Med：钙通道阻滞剂可以降低脓毒症的死亡率

实验研究表明钙通道阻滞剂可以改善败血症的结果。近期一项发表在Crit Care Med杂志上的文章进行了一项前瞻性研究，研究了提前使用的钙通道阻滞剂与ICU中脓毒症患者的治疗结果之间的关联。此项研究选取了荷兰3家ICU医院，共分析了1060名脓毒症患者，其中18.6％的患者使用钙通道阻滞剂。研究者们测量了患者在入院后的前4天内的15个血浆生物标志物水平，提供了与脓毒病发病相关的关键宿主反应的指标。